BDSX

Biodesix announced a strategic partnership with Vanderbilt University to develop a radiomics-based test for lung nodule risk assessment that combines blood-based and imaging biomarkers using AI. The first product is expected to be commercially available in 2028, with initial data presented at RSNA in December 2026. This initiative expands Biodesix's lung diagnostics platform and positions the company to develop multimodal solutions across various pulmonary diseases.

Biodesix announced multiple presentations at CHEST 2026 showcasing real-world evidence for integrating Nodify Lung blood-based testing into routine lung nodule management. The presentations include sponsored research comparing biomarkers with PET imaging, independent studies on patient follow-up adherence, and analyses from the CLARIFY study involving over 2,000 patients. The company is demonstrating how blood-based biomarkers can be incorporated into structured care pathways alongside imaging.

Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.